A cell and gene therapy CDMO engaged Pharmatech to relocate manufacturing and analytical processes for eight therapies. We managed risk assessments, authored protocols and batch records, and oversaw readiness activities.
Impact for the client:
- All eight programs successfully transferred
- Regulatory alignment maintained
- Audit-ready transition completed on schedule
